Tedizolid Phosphate is an oxazolidinone antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.
There is little patient-to-patient variability in the concentration of tedizolid phosphate in blood, as compared to linezolid. As a result, we expect that tedizolid phosphate will have more predictable drug exposure which may lead to a more uniform efficacy and safety profile across different patients when compared to linezolid.
Mode of Action:
After conversion to its active form by phosphatases, tedizolid exerts its antibacterial activity through inhibition of protein synthesis by binding to the 50S ribosomal subunit of susceptible Gram-positive bacteria. Cross-resistance between other non-oxazolidinone antibacterial drugs is unlikely as it inhibits bacterial protein synthesis through a different mechanism.
Tedizolid phosphate is a prodrug that is converted by phosphatases to tedizolid, it’s microbiologically active form. There are no other significant circulating metabolites beyond tedizolid which accounts for approximately 95% of the AUC. It is also unlikely to be metabolized by CYP450 enzymes in the liver.
The most commonly reported adverse effects were nausea, vomiting, diarrhea, nausea, and dizziness. Other reactions that occurred during clinical trials at a rate less than 2% include anemia, tachycardia, blurred vision, oral candidiasis, colitis, decreased white blood cell count, vulvovaginal mycotic infection, paresthesia, hypertension, and urticaria. There are no adequate studies to confirm that tedizolid phosphate is safe to use during pregnancy and should be avoided as it was shown to produce fetal developmental toxicities in mice, rats, and rabbits.
Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, Prokocimer P: Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014 Aug;42(8):1275-84. doi: 10.1124/dmd.113.056697. Epub 2014 May 29. [PubMed:24875463 ] Michalska K, Karpiuk I, Krol M, Tyski S: Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem. 2013 Feb 1;21(3):577-91. doi: 10.1016/j.bmc.2012.11.036. Epub 2012 Dec 5. [PubMed:23273607 ] Rybak JM, Roberts K: Tedizolid Phosphate: a Next-Generation Oxazolidinone. Infect Dis Ther. 2015 Feb 24. [PubMed:25708156 ] Gras J: Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. Drugs Today (Barc). 2014 Nov;50(11):729-37. doi: 10.1358/dot.2014.50.11.2233783. [PubMed:25525633 ] Flanagan S, Fang E, Munoz KA, Minassian SL, Prokocimer PG: Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy. 2014 Sep;34(9):891-900. doi: 10.1002/phar.1458. Epub 2014 Jul 3. [PubMed:24989138 ]
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs